Short Interest in Journey Medical Co. (NASDAQ:DERM) Grows By 14.8%

Journey Medical Co. (NASDAQ:DERM) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 76,800 shares, a growth of 14.8% from the December 31st total of 66,900 shares. Based on an average daily volume of 108,900 shares, the short-interest ratio is presently 0.7 days. Currently, 0.8% of the shares of the company are sold short.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. PVG Asset Management Corp increased its stake in shares of Journey Medical by 5.7% during the 3rd quarter. PVG Asset Management Corp now owns 167,545 shares of the company’s stock worth $947,000 after purchasing an additional 9,005 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Journey Medical by 13.5% during the 3rd quarter. Geode Capital Management LLC now owns 108,435 shares of the company’s stock worth $613,000 after buying an additional 12,882 shares during the period. Kovitz Investment Group Partners LLC bought a new stake in shares of Journey Medical during the 3rd quarter worth about $66,000. Nwam LLC bought a new stake in shares of Journey Medical during the 3rd quarter worth about $59,000. Finally, ORG Wealth Partners LLC bought a new stake in shares of Journey Medical during the 3rd quarter worth about $110,000. 7.25% of the stock is currently owned by institutional investors and hedge funds.

Journey Medical Stock Up 14.3 %

Journey Medical stock opened at $4.55 on Monday. The firm has a market capitalization of $95.05 million, a PE ratio of -4.84 and a beta of 1.00. The company’s 50-day moving average is $4.53 and its 200-day moving average is $5.06. Journey Medical has a fifty-two week low of $2.85 and a fifty-two week high of $6.89. The company has a debt-to-equity ratio of 1.81, a current ratio of 1.38 and a quick ratio of 1.03.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.